Genetic-guided weaker blood thinner vs stronger standard therapy
Part of Heart & circulation clinical trials.
This study tests whether switching early to a weaker anti-platelet medicine based on your genetics can reduce bleeding problems in people at high risk for bleeding after a heart attack. It compares this approach to the usual strategy of staying on a stronger anti-platelet medicine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and were recently admitted for a heart attack (type 1 STEMI or NSTEMI).
- In the hospital, you can have a quick genetic test for clopidogrel resistance (results within about 1 hour).
- You are currently taking aspirin plus ticagrelor OR aspirin plus prasugrel, at screening and at the randomization visit.
- You have high bleeding risk, such as: age 75+; low hemoglobin/anemia; significant kidney disease; low platelets; certain bleeding disorders; liver cirrhosis with portal hypertension; recent stroke; recent bleeding or transfusion; certain recent cancers; or planned long-term pain/anti-inflammatory medicines (NSAIDs) or steroids after PCI.
- You should not join if you: are on a blood thinner (like apixaban/rivaroxaban/dabigatran or warfarin), have ever had a bleeding in the brain, have a known allergy or interaction risk with clopidogrel, plan surgery soon (within 12 months), cannot sign consent, are pregnant/breastfeeding, or are in certain legal guardianship situations.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 4 study tests whether using a reduced blood-thinner (antithrombotic) strategy after a heart attack can lower bleeding without losing heart protection. It is mainly for people considered high risk for bleeding after getting a stent.
This trial tests whether a genetic test can help doctors choose the best blood-thinning medicine for people with heart disease who are having a stent placed. The goal is to reduce the risk of blood clots or bleeding after the procedure.
This trial tests whether choosing a shorter blood thinner treatment based on your genes, or reducing the dose, is safe and works well for people with high bleeding risk after getting a stent for a heart attack or chest pain.
This study tests whether tailoring blood-thinner medication based on a cheek swab can improve recovery after having a heart stent placed. Participants will be randomly assigned to one of two blood thinners, and their treatment will be adjusted based on genetic testing.
This trial tests whether choosing a blood thinner based on your DNA can prevent more heart problems. If you've had a complex heart procedure, you may be able to get a medication that works best for your body.
This trial tests whether tailoring anti-platelet (blood clot prevention) treatment can better protect people at higher risk of heart or blood-vessel problems after a drug-eluting stent. It may help prevent future clots and complications, especially in patients with certain high-risk health conditions or complex stent/scar tissue features.
Hear when a new MYOCARDIAL INFARCTION trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.